Oncoinvent ASA (ONCIN) - Total Assets
Based on the latest financial reports, Oncoinvent ASA (ONCIN) holds total assets worth Nkr204.96 Million NOK (≈ $21.57 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Oncoinvent ASA (ONCIN) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Oncoinvent ASA - Total Assets Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's total assets have evolved over time, based on quarterly financial data. See ONCIN total equity for net asset value and shareholders' equity analysis.
Oncoinvent ASA - Asset Composition Analysis
Current Asset Composition (December 2025)
Oncoinvent ASA's total assets of Nkr204.96 Million consist of 91.4% current assets and 8.6% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr177.60 Million | 86.7% |
| Accounts Receivable | Nkr992.00K | 0.5% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr15.58 Million | 7.6% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Oncoinvent ASA market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncoinvent ASA's current assets represent 91.4% of total assets in 2025, a decrease from 99.7% in 2021.
- Cash Position: Cash and equivalents constituted 86.7% of total assets in 2025, down from 96.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is cash and equivalents at 86.7% of total assets.
Oncoinvent ASA Competitors by Total Assets
Key competitors of Oncoinvent ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Oncoinvent ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.23 | 4.79 | 5.05 |
| Quick Ratio | 3.23 | 4.79 | 5.05 |
| Cash Ratio | 0.00 | 4.34 | 0.00 |
| Working Capital | Nkr129.35 Million | Nkr122.27 Million | Nkr175.04 Million |
Oncoinvent ASA - Advanced Valuation Insights
This section examines the relationship between Oncoinvent ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 19.8% |
| Total Assets | Nkr204.96 Million |
| Market Capitalization | $38.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncoinvent ASA's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oncoinvent ASA's assets grew by 19.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oncoinvent ASA (2021–2025)
The table below shows the annual total assets of Oncoinvent ASA from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr204.96 Million ≈ $21.57 Million |
+19.85% |
| 2024-12-31 | Nkr171.01 Million ≈ $18.00 Million |
-1.90% |
| 2023-12-31 | Nkr174.34 Million ≈ $18.35 Million |
+4.58% |
| 2022-12-31 | Nkr166.71 Million ≈ $17.54 Million |
-62.97% |
| 2021-12-31 | Nkr450.24 Million ≈ $47.38 Million |
-- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.